ExploreWatchlistsPricing
  1. JP-listed companies
  2. CellSeed Inc.
  3. Financials
  4. Net income

CellSeed Inc. (7776)

Market cap
¥11.5B
P/E ratio
-9.8x
Cellseed develops cell sheet regenerative medicine technology to treat diseases that conventional therapies cannot cure, serving researchers and patients globally.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Dec 31, 2025-1,104+28.41%
Dec 31, 2024-860+1.57%
Dec 31, 2023-847+11.43%
Dec 31, 2022-760-16.93%
Dec 31, 2021-915+16.67%
Dec 31, 2020-784+0.19%
Dec 31, 2019-782-703.03%
Dec 31, 2018130-113.42%
Dec 31, 2017-966-31.66%
Dec 31, 2016-1,414+164.22%
Dec 31, 2015-535-8.14%
Dec 31, 2014-583-0.32%
Dec 31, 2013-585-35.99%
Dec 31, 2012-913-36.67%
Dec 31, 2011-1,442

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat